Skip to main content
All Companies Ticker CABA
Below our coverage size floor
You reached the page — here's exactly what CABA is, and why it's out of scope for now.
What this ticker is
CABA Cabaletta Bio Inc.
NASDAQ Healthcare Biotechnology United States Mkt cap $454.9M
Cabaletta Bio Inc. is a clinical-stage biotechnology company specializing in engineered T cell therapies for B cell–mediated autoimmune diseases. The company focuses on leveraging its proprietary CABA platform, which includes two main approaches: CARTA, or chimeric antigen receptor T cells for autoimmunity, and CAART, or chimeric autoantibody receptor T cel…
Why we can't analyze it yet
Below business size floor — market cap $454,922,880 is under our $500,000,000 coverage minimum
Delvantic analyzes regular securities of single operating companies — one business with revenue, earnings and cash flows our valuation methods can assess bottom-up.
Reason code: below_coverage